Faculty of Medicine, Department of Medical Biology, Cumhuriyet University, 58140, Sivas, Turkey.
Med Oncol. 2011 Dec;28(4):1373-8. doi: 10.1007/s12032-010-9588-y. Epub 2010 Nov 11.
Polymorphism of AXIN2, a component of Wnt signaling, has been shown to play a role in tumorigenesis and dysregulated in cancer cells. In order to find out if AXIN2 polymorphism is a risk factor for prostate cancer, we analyzed eight polymorphic regions of this gene in 84 patients with prostate cancer and compared the results with 100 healthy controls in a Turkish population using PCR-RFLP methods. The genotype frequencies and risk factors of prostate cancer and control groups were analyzed by Chi-square test. We found a statistically significant result between prostate cancer risk and AXIN2 Intron2-956+16A/G (rs35285779) SNP. The frequency of the homozygous G/G (0%) and heterozygous A/G (18%) genotypes was significantly less in patients with prostate cancer than in healthy controls (7 and 32%, respectively) (P<0.05) for this SNP. When compared with the wild-type A/A genotype of the controls, prostate cancer patients with the A/G and G/G genotype showed reduced risk of cancer; the adjusted odds ratio (OR) for patients with the homozygous G/G genotype was 0.87 (95% CI: 0.81-0.95) and for heterozygous A/G genotype was 0.42 (95% CI: 0.20-0.85). We found no statistically significant association between controls and prostate cancer for other seven SNPs of AXIN2 including Exon1-148 C/T (rs2240308), Exon1-432 T/C (rs2240308), Exon5-1365 G/A (rs9915936), Exon5-1386 C/T (rs1133683), Intron5-1712+19 T/G, Exon7-2062 C/T, and Intron7-2141+73 G/A (rs4072245) (P>0.05). These results suggest that the AXIN2 Intron2 rs35285779 SNP is associated with development of prostate cancer as a protective SNP, while an association between other seven SNPs of the AXIN2 and risk of prostate cancer was not observed.
AXIN2 是 Wnt 信号通路的一个组成部分，其多态性已被证明在肿瘤发生中起作用，并在癌细胞中失调。为了确定 AXIN2 多态性是否是前列腺癌的危险因素，我们在土耳其人群中使用 PCR-RFLP 方法分析了 84 例前列腺癌患者和 100 例健康对照者的该基因的 8 个多态区域。使用卡方检验分析前列腺癌和对照组的基因型频率和危险因素。我们发现 AXIN2 内含子 2-956+16A/G(rs35285779)SNP 与前列腺癌风险之间存在统计学显著结果。与健康对照组相比，前列腺癌患者中纯合子 G/G(0%)和杂合子 A/G(18%)基因型的频率显著降低(分别为 7%和 32%)(P<0.05)。与对照组的野生型 A/A 基因型相比，携带 A/G 和 G/G 基因型的前列腺癌患者癌症风险降低;纯合子 G/G 基因型患者的调整优势比(OR)为 0.87(95%CI:0.81-0.95)，杂合子 A/G 基因型患者的 OR 为 0.42(95%CI:0.20-0.85)。我们未发现 AXIN2 的其他七个 SNP(包括外显子 1-148C/T(rs2240308)、外显子 1-432T/C(rs2240308)、外显子 5-1365G/A(rs9915936)、外显子 5-1386C/T(rs1133683)、内含子 5-1712+19T/G、外显子 7-2062C/T 和内含子 7-2141+73G/A(rs4072245))与对照组和前列腺癌之间存在统计学显著相关性(P>0.05)。这些结果表明，AXIN2 内含子 2 rs35285779SNP 作为一种保护性 SNP 与前列腺癌的发生有关，而 AXIN2 的其他七个 SNP 与前列腺癌的风险之间没有关联。
